Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape

SARS-CoV-2, the causative agent of COVID-19, has been responsible for a global pandemic. Monoclonal antibodies have been used as antiviral therapeutics, but have been limited in efficacy by viral sequence variability in emerging variants of concern (VOCs), and in deployment by the need for high dose...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2022-10
Main Authors: Clare Burn Aschner, Muthuraman, Krithika, Iga Kucharska, Cui, Hong, Prieto, Katherine, Nair, Manoj S, Wang, Maple, Huang, Yaoxing, Christie-Holmes, Natasha, Poon, Betty, Lam, Jessica, Sultana, Azmiri, Kozak, Robert, Mubareka, Samira, Rubinstein, John L, Rujas, Edurne, Treanor, Bebhinn, Ho, David D, Jetha, Arif, Jean-Philippe, Julien
Format: Article
Language:English
Subjects:
Antibodies
Apoferritin
Avidity
COVID-19
Immunotherapy
Monoclonal antibodies
Severe acute respiratory syndrome coronavirus 2
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2, the causative agent of COVID-19, has been responsible for a global pandemic. Monoclonal antibodies have been used as antiviral therapeutics, but have been limited in efficacy by viral sequence variability in emerging variants of concern (VOCs), and in deployment by the need for high doses. In this study, we leverage the MULTI-specific, multi-Affinity antiBODY (Multabody, MB) platform, derived from the human apoferritin protomer, to drive the multimerization of antibody fragments and generate exceptionally potent and broad SARS-CoV-2 neutralizers. CryoEM revealed a high degree of homogeneity for the core of these engineered antibody-like molecules at 2.1 Å resolution. We demonstrate that neutralization potency improvements of the MB over corresponding IgGs translates into superior in vivo protection: in the SARS-CoV-2 mouse challenge model, comparable in vivo protection was achieved for the MB delivered at 30x lower dose compared to the corresponding IgGs. Furthermore, we show how MBs potently neutralize SARS-CoV-2 VOCs by leveraging augmented avidity, even when corresponding IgGs lose their ability to neutralize potently. Multiple mAb specificities could also be combined into a single MB molecule to expand the neutralization breadth beyond SARS-CoV-2 to other sarbecoviruses. Our work demonstrates how avidity and multi-specificity combined can be leveraged to confer protection and resilience against viral diversity that exceeds that of traditional monoclonal antibody therapies. Competing Interest Statement The Hospital for Sick Children has applied for patents concerning 298, 52 and 80 SARS-CoV-2 antibodies and the Multabody platform technology that are related to this work. B.T. and J.-P.J. are founders of Radiant Biotherapeutics and are members of its Scientific Advisory Board. D.D.H., M.S.N., and Y.H., are inventors of a patent describing some of the antibodies reported in this work. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics and Brii Biosciences, and board director for Vicarious Surgical. All other authors declare that they have no competing interests.
DOI:10.1101/2022.10.23.513379